Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 2/20 | 0.35 |
| ▸ | CFB | P00751 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925477 | 0.91 | HTR5A (0.46) | HTR5AKDM4EALDH1A1HPGDPLAU | |
| SCHEMBL9909257 | 0.87 | SLC22A12 (0.42) | HTR5AKDM4EALDH1A1HPGDCFB | |
| SCHEMBL9909238 | 0.83 | ALDH1A1 (0.47) | KDM4EALDH1A1HPGD | |
| SCHEMBL9909242 | 0.83 | HTR5A (0.59) | HTR5APLAUSCN9A | |
| SCHEMBL10064021 | 0.81 | HTR5A (0.39) | HTR5APLAUHTR7HTR2BSLC9A1 | |
| SCHEMBL16509508 | 0.80 | PLAU (0.41) | HTR5APLAUHTR7HTR2BSLC9A1 | |
| SCHEMBL9909299 | 0.80 | SCN9A (0.45) | HTR5APLAUSCN9A | |
| SCHEMBL16494659 | 0.78 | HTR5A (0.42) | HTR5APLAUHTR7HTR2BSCN9A | |
| SCHEMBL9909305 | 0.76 | HTR5A (0.70) | HTR5AHTR7HTR2BSLC9A1 | |
| SCHEMBL16509515 | 0.76 | HTR5A (0.48) | HTR5APLAUSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885KDM4E 1474/4885ALDH1A1 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.